CryoPort (NASDAQ:CYRX) Upgraded at Wall Street Zen

Key Points

• CryoPort was upgraded by Wall Street Zen from “sell” to “hold”, adding to a generally positive analyst backdrop for the stock.
• Several other firms recently raised their outlooks and price targets, including Needham, BTIG, and Guggenheim; overall, the stock now has an average analyst rating of Moderate Buy with a $14.44 average price target.
• The company reported its latest quarterly results with revenue of $47.8 million, topping estimates, but EPS of -$0.23 missed expectations. CryoPort also saw insider selling and strong institutional ownership, with institutions holding 92.9% of shares.

CryoPort (NASDAQ:CYRX - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Monday.

A number of other equities analysts have also recently commented on the company. Craig Hallum assumed coverage on CryoPort in a report on Monday, March 30th. They set a "buy" rating and a $15.00 price target for the company. Needham & Company LLC lifted their price target on CryoPort from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday, May 5th. BTIG Research lifted their price target on CryoPort from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Tuesday, May 5th. Guggenheim lifted their price target on CryoPort from $11.00 to $12.00 and gave the stock a "buy" rating in a report on Tuesday, May 5th. Finally, Weiss Ratings upgraded CryoPort from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $14.44.

CryoPort Stock Performance

NASDAQ:CYRX opened at $13.60 on Monday. The stock's 50-day simple moving average is $9.17 and its 200 day simple moving average is $9.37. The company has a market cap of $685.44 million, a P/E ratio of 10.07 and a beta of 1.75. CryoPort has a 52-week low of $5.31 and a 52-week high of $13.68.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The business had revenue of $47.80 million for the quarter, compared to the consensus estimate of $44.86 million. As a group, equities analysts predict that CryoPort will post -0.74 earnings per share for the current fiscal year.

Insider Transactions at CryoPort

In other news, CFO Robert Stefanovich sold 38,700 shares of the business's stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $7.76, for a total transaction of $300,312.00. Following the completion of the sale, the chief financial officer owned 255,701 shares in the company, valued at $1,984,239.76. The trade was a 13.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Mark W. Sawicki sold 3,235 shares of the business's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $8.00, for a total value of $25,880.00. Following the sale, the insider owned 103,697 shares of the company's stock, valued at approximately $829,576. This represents a 3.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 59,939 shares of company stock worth $471,183 over the last quarter. Company insiders own 10.10% of the company's stock.

Institutional Investors Weigh In On CryoPort

A number of institutional investors have recently made changes to their positions in CYRX. Mak Capital One LLC bought a new stake in shares of CryoPort during the third quarter worth approximately $7,756,000. UBS Group AG boosted its holdings in shares of CryoPort by 112.7% during the third quarter. UBS Group AG now owns 1,331,521 shares of the company's stock worth $12,623,000 after acquiring an additional 705,649 shares during the period. Millennium Management LLC boosted its holdings in shares of CryoPort by 23.8% during the fourth quarter. Millennium Management LLC now owns 3,244,802 shares of the company's stock worth $31,150,000 after acquiring an additional 623,896 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in shares of CryoPort by 283.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company's stock worth $4,970,000 after acquiring an additional 387,440 shares during the period. Finally, First Eagle Investment Management LLC bought a new stake in shares of CryoPort during the fourth quarter worth approximately $2,996,000. Institutional investors own 92.90% of the company's stock.

CryoPort Company Profile

CryoPort, Inc NASDAQ: CYRX is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.